GeoVax Labs, Inc. (Nasdaq: GOVX) is a clinical-stage biotechnology company with a robust pipeline of human vaccines and immunotherapies to address unmet medical needs in cancer and infectious disease.

Our products are based upon a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying several vaccine antigens, expresses proteins that assemble into VLP immunogens within (in vivo) the person receiving the vaccine.

The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.

The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector. Read more about our technology here.

Our preventive vaccine against HIV is progressing in human clinical trials with the support of the National Institutes of Health (NIH), and we are also part of collaborative efforts to develop an immunotherapy as a functional cure for HIV. Other vaccines and immunotherapies are in various stages of preclinical development.  Read more about our product pipeline here and about our collaborations here.